Raltegravir switch improves hepatitis C transaminitis in HIV-1 and hepatitis C (HCV) co-infected individuals by M Cevik et al.
Poster Abstract  P131
Raltegravir switch improves hepatitis C transaminitis in HIV-1 and
hepatitis C (HCV) co-infected individuals
Cevik, M
1; Jagjit Singh, G
1; Dickinson, L
2 and Nelson, M
1
1Chelsea and Westminster Hospital, London, UK.
2University of Liverpool, Liverpool, UK.
Purpose of the study
HCV is one of the most relevant co-morbidities seen in HIV-infected individuals as evidenced by the negative impact that HIV
exerts on the course of HCV infection. Despite remarkable results on HIV infection alone, the impact of highly active
antiretroviral therapy (HAART) on liver disease in co-infection remains unknown. We sought to explore the impact of raltegravir
(RAL) on amino transferase (ALT) in HIV/HCV co-infected individuals.
Methods
HIV-infected individuals co-infected with HCV within the last 5 years receiving non-integrase inhibitor containing HAART with a
subsequent switch to RAL-containing HAART were identified from a retrospectively maintained outpatient database. Patient
demographics were extracted. Biochemical, virological and immunological parameters were collated and individuals received
pegylated interferon with ribavirin were excluded. ALT levels at switch and post switch were compared using Kruskal-Wallis test.
Spearman’s Rank correlation was used to assess the relationship between ALT and HCV-RNA.
Summary of results
Twenty-sevenHIV-HCVco-infectedindividualswereidentifiedbetweenJanuary2007andJanuary2012andsevenindividualswere
excluded. Median age was44 years (range: 3168).Five hadacute andfifteenhadchronic HCV infectionduringthe switch.Twenty
(100%) had HIV-RNA-1B40 copies/mL at time of RAL switch. In chronic HCV infected individuals, median ALT levels at the time of
switch were 465 IU/L, decreased significantly to 179 IU/L 1 month following switch (p0.0261) and to 140 IU/L 6 months later
(p0.0225). On the other hand, in acute HCV infected individuals median ALT levels were 1005 IU/L at time of switch but
decreasedsignificantlyto220IU/L1monthlater(p0.0034)andto35IU/L6monthlater(p0.0026).Sustainedimprovementin
ALT levels from baseline to 1 month and up to 24 weeks after switch to RALwas observed in both groups but the reduction in ALT
levels was statistically more significant in acutely infected individuals. ALTand HCV-RNA levels showed a positive correlation at 6
months pre, post and at time of switch both in acute and chronic HCV-infected individuals (Spearman’s Rank correlation).
Conclusion
In our study, RAL had a favourable effect on the liver up to 24 weeks after switch in HIV/HCV infected individuals.
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